The “Suite Ride” experiment conducted during the Axiom Mission 4 (Ax-4) aboard the International Space Station has revealed groundbreaking results: diabetics can safely travel and be monitored in space using everyday diabetes management tools.

This finding opens the door for astronauts with diabetes to participate in space missions, a feat earlier considered unachievable.

The research, pioneered as a collaboration between Axiom Space and UAE-based Burjeel Holdings, demonstrated that continuous glucose monitors (CGMs) and insulin pens function reliably in the microgravity environment of space.

During the Ax-4 mission, Indian astronaut Shubhanshu Shukla and the crew used CGMs to monitor glucose levels in real-time, with readings showing comparable accuracy to Earth-based devices. Additio

See Full Page